Tech Transfer eNews Blog

Harvard, Soligenix ink anthrax vaccine development pact

By David Schwartz
Published: December 21st, 2011

Princeton, NJ-based biopharmaceutical company Soligenix, Inc., has initiated a next-generation anthrax vaccine development program by exercising an exclusive option agreement with Harvard University to negotiate a license under patent rights covering prophylactic uses of a modified anthrax toxin protein. Initial development work on thermo-stable ricin and anthrax vaccines will be covered through a $9.4-million National Institute of Allergy and Infectious Disease grant.

The option agreement encompasses an issued U.S. patent that covers engineered variants of protective antigen (PA) developed in the laboratory of Harvard professor John Collier. PA is the principal determinant of protective immunity to anthrax. Soligenix hopes to develop the Collier anthrax vaccine with an efficacy profile superior to other anthrax vaccines.

Source:  Yahoo Finance

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment